Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

Antonio M. Gotto, Stephen J. Boccuzzi, John R. Cook, Charles M. Alexander, James B. Roehm, Gregg S. Meyer, Michael Clearfield, Stephen Weis, Edwin Whitney

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

This cost-consequences analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study compares the costs of lovastatin treatment with the costs of cardiovascular hospitalizations and procedures. The cost of lovastatin treatment was defined as the average retail price and the cost of drug safety monitoring and adverse experiences. Costs were determined by actual rates of hospitalizations and procedures. Within a trial, lovastatin treatment cost approximately $4,654/patient. Lovastatin treatment significantly reduced the cumulative rate of cardiovascular hospitalizations and procedures (p = 0.002). Over the duration of the study, the cumulative number of cardiovascular hospitalizations and related therapeutic procedures was significantly reduced by 29%. The time to first cardiovascular-related hospitalization or procedure was significantly extended by lovastatin (p = 0.002). Lovastatin reduced the frequency of cardiovascular hospitalization (28%), and cardiovascular therapeutic (32%) and diagnostic procedures (23%). Among therapeutic procedures, treatment reduced coronary artery bypass graft surgery by 19% and percutaneous transluminal coronary angioplasty by 37%. Total cardiovascular-related hospital days were reduced by 26% (p = 0.025). The between-group offset in direct medical costs was $524, which resulted in a 11% cost offset of lovastatin therapy over the mean study duration of 5.2 years. Lovastatin provides meaningful reductions in cardiovascular-related resource utilization and reductions in direct cardiovascular-related costs associated with the onset of coronary disease. (C) 2000 by Excerpta Medica, Inc.

Original languageEnglish
Pages (from-to)1176-1181
Number of pages6
JournalAmerican Journal of Cardiology
Volume86
Issue number11
DOIs
StatePublished - 1 Dec 2000

Fingerprint

Lovastatin
Coronary Artery Disease
Air
Costs and Cost Analysis
Hospitalization
Health Care Costs
Therapeutics
Coronary Balloon Angioplasty
Drug Monitoring
Coronary Artery Bypass
Coronary Disease
Transplants
Safety

Cite this

Gotto, Antonio M. ; Boccuzzi, Stephen J. ; Cook, John R. ; Alexander, Charles M. ; Roehm, James B. ; Meyer, Gregg S. ; Clearfield, Michael ; Weis, Stephen ; Whitney, Edwin. / Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). In: American Journal of Cardiology. 2000 ; Vol. 86, No. 11. pp. 1176-1181.
@article{f8c856ce3f614c5b93ef616b3140751e,
title = "Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)",
abstract = "This cost-consequences analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study compares the costs of lovastatin treatment with the costs of cardiovascular hospitalizations and procedures. The cost of lovastatin treatment was defined as the average retail price and the cost of drug safety monitoring and adverse experiences. Costs were determined by actual rates of hospitalizations and procedures. Within a trial, lovastatin treatment cost approximately $4,654/patient. Lovastatin treatment significantly reduced the cumulative rate of cardiovascular hospitalizations and procedures (p = 0.002). Over the duration of the study, the cumulative number of cardiovascular hospitalizations and related therapeutic procedures was significantly reduced by 29{\%}. The time to first cardiovascular-related hospitalization or procedure was significantly extended by lovastatin (p = 0.002). Lovastatin reduced the frequency of cardiovascular hospitalization (28{\%}), and cardiovascular therapeutic (32{\%}) and diagnostic procedures (23{\%}). Among therapeutic procedures, treatment reduced coronary artery bypass graft surgery by 19{\%} and percutaneous transluminal coronary angioplasty by 37{\%}. Total cardiovascular-related hospital days were reduced by 26{\%} (p = 0.025). The between-group offset in direct medical costs was $524, which resulted in a 11{\%} cost offset of lovastatin therapy over the mean study duration of 5.2 years. Lovastatin provides meaningful reductions in cardiovascular-related resource utilization and reductions in direct cardiovascular-related costs associated with the onset of coronary disease. (C) 2000 by Excerpta Medica, Inc.",
author = "Gotto, {Antonio M.} and Boccuzzi, {Stephen J.} and Cook, {John R.} and Alexander, {Charles M.} and Roehm, {James B.} and Meyer, {Gregg S.} and Michael Clearfield and Stephen Weis and Edwin Whitney",
year = "2000",
month = "12",
day = "1",
doi = "10.1016/S0002-9149(00)01198-X",
language = "English",
volume = "86",
pages = "1176--1181",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "11",

}

Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). / Gotto, Antonio M.; Boccuzzi, Stephen J.; Cook, John R.; Alexander, Charles M.; Roehm, James B.; Meyer, Gregg S.; Clearfield, Michael; Weis, Stephen; Whitney, Edwin.

In: American Journal of Cardiology, Vol. 86, No. 11, 01.12.2000, p. 1176-1181.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

AU - Gotto, Antonio M.

AU - Boccuzzi, Stephen J.

AU - Cook, John R.

AU - Alexander, Charles M.

AU - Roehm, James B.

AU - Meyer, Gregg S.

AU - Clearfield, Michael

AU - Weis, Stephen

AU - Whitney, Edwin

PY - 2000/12/1

Y1 - 2000/12/1

N2 - This cost-consequences analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study compares the costs of lovastatin treatment with the costs of cardiovascular hospitalizations and procedures. The cost of lovastatin treatment was defined as the average retail price and the cost of drug safety monitoring and adverse experiences. Costs were determined by actual rates of hospitalizations and procedures. Within a trial, lovastatin treatment cost approximately $4,654/patient. Lovastatin treatment significantly reduced the cumulative rate of cardiovascular hospitalizations and procedures (p = 0.002). Over the duration of the study, the cumulative number of cardiovascular hospitalizations and related therapeutic procedures was significantly reduced by 29%. The time to first cardiovascular-related hospitalization or procedure was significantly extended by lovastatin (p = 0.002). Lovastatin reduced the frequency of cardiovascular hospitalization (28%), and cardiovascular therapeutic (32%) and diagnostic procedures (23%). Among therapeutic procedures, treatment reduced coronary artery bypass graft surgery by 19% and percutaneous transluminal coronary angioplasty by 37%. Total cardiovascular-related hospital days were reduced by 26% (p = 0.025). The between-group offset in direct medical costs was $524, which resulted in a 11% cost offset of lovastatin therapy over the mean study duration of 5.2 years. Lovastatin provides meaningful reductions in cardiovascular-related resource utilization and reductions in direct cardiovascular-related costs associated with the onset of coronary disease. (C) 2000 by Excerpta Medica, Inc.

AB - This cost-consequences analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study compares the costs of lovastatin treatment with the costs of cardiovascular hospitalizations and procedures. The cost of lovastatin treatment was defined as the average retail price and the cost of drug safety monitoring and adverse experiences. Costs were determined by actual rates of hospitalizations and procedures. Within a trial, lovastatin treatment cost approximately $4,654/patient. Lovastatin treatment significantly reduced the cumulative rate of cardiovascular hospitalizations and procedures (p = 0.002). Over the duration of the study, the cumulative number of cardiovascular hospitalizations and related therapeutic procedures was significantly reduced by 29%. The time to first cardiovascular-related hospitalization or procedure was significantly extended by lovastatin (p = 0.002). Lovastatin reduced the frequency of cardiovascular hospitalization (28%), and cardiovascular therapeutic (32%) and diagnostic procedures (23%). Among therapeutic procedures, treatment reduced coronary artery bypass graft surgery by 19% and percutaneous transluminal coronary angioplasty by 37%. Total cardiovascular-related hospital days were reduced by 26% (p = 0.025). The between-group offset in direct medical costs was $524, which resulted in a 11% cost offset of lovastatin therapy over the mean study duration of 5.2 years. Lovastatin provides meaningful reductions in cardiovascular-related resource utilization and reductions in direct cardiovascular-related costs associated with the onset of coronary disease. (C) 2000 by Excerpta Medica, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034564091&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(00)01198-X

DO - 10.1016/S0002-9149(00)01198-X

M3 - Article

C2 - 11090787

AN - SCOPUS:0034564091

VL - 86

SP - 1176

EP - 1181

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 11

ER -